

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3627044

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	12/18/2009

CONVEYING PARTY DATA

Name	Execution Date
GUANGWEN WEI	10/22/2015
DACHENG WANG	10/22/2015

RECEIVING PARTY DATA

Name:	SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.
Street Address:	SUITE 402, YINHAIXINZUO, 163 SANSE ROAD, JINJIANG DISTRICT
City:	CHENGDU, SICHUAN
State/Country:	CHINA
Postal Code:	610063

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	8415151

CORRESPONDENCE DATA**Fax Number:**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: docketing@kitchanlaw.com**Correspondent Name:** LAW OFFICES OF ALBERT WAI-KIT CHAN, PLLC**Address Line 1:** 141-07 20TH AVENUE, WHITESTONE**Address Line 2:** WORLD PLAZA, SUITE 604**Address Line 4:** NEW YORK, NEW YORK 11357

ATTORNEY DOCKET NUMBER:	1394-B-US
NAME OF SUBMITTER:	ALBERT WAI-KIT-CHAN
SIGNATURE:	/Albert Wai-Kit-Chan/
DATE SIGNED:	11/20/2015

Total Attachments: 7

source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page1.tif
source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page2.tif
source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page3.tif
source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page4.tif

source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page5.tif

source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page6.tif

source=1394 Assignment to Sichuan Huiyanglife (2015-10-22)#page7.tif

NUNC PRO TUNC ASSIGNMENT

In consideration of the mutual covenants herein contained and other good and valuable consideration, the mutual receipt and legal sufficiency of which are hereby acknowledged, we, the undersigned,

Guangwen WEI, residing at **Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's Republic of China**; and

Dacheng WANG, residing at **No. 15, Datun Road, Chaoyang District, Beijing, 100101, People's Republic of China** (hereinafter collectively as "ASSIGNOR").

Hereby sell, assign and transfer, nunc pro tunc as of December 18, 2009, to **Sichuan Huiyang Life Science & Technology Corp.**, a corporation of **People's Republic of China**, having a place of business at **Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's Republic of China**, and to its successors and assigns (hereinafter referred to collectively as "ASSIGNEE") the entire right, title and interest for all countries of the world, in and to any of the following:

(1) any and all inventions and discoveries which are disclosed and claimed, and any and all inventions and discoveries which are disclosed but not claimed in the patent applications identified on **Schedule A** hereto;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including but not limited to, all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) or (2) in all countries and regions, and the right to file any patent, utility model, or other applications in all countries and regions claiming the priority of any of the applications identified in paragraphs (1) or (2), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement, or understanding;

(4) all divisional, continuation, continuation-in-part, substitute, renewal, reissue, and reexamination of any United States patent application(s), international patent application(s), any national stages of said international application(s), and all other applications for patent or other related property rights in any and all countries which have been or shall be filed on any of the inventions and discoveries disclosed in any of the applications of foregoing paragraphs (1) to (2);

(5) all original and reissued patents, renewals and extensions of said patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances that issue from any of the applications referred to herein, and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under any law permitting remedies for infringement prior to issuance of the patent;

(6) all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of any item in any of the foregoing

paragraphs (1) through (5), including, without limitation, all causes of action and other enforcement rights for (i) damages, (ii) injunctive relief, and (iii) any other remedies of any kind for past, current, and future infringement. This Assignment includes the right, in the sole discretion of the Assignee and without any economic benefits retained to the Assignor, to bring suit to recover for past damages, to settle infringement claims, and to license said Patent Rights; and

(7) all rights to collect royalties and other payments under or on account of any item in any of the foregoing paragraphs (1) through (6).

ASSIGNOR has entered into an assignment agreement date September 3, 2012 ("Assignment-A") to sell and assign to ASSIGNEE the entire rights, titles and interests in Canada in and to the invention described in the International Application No. PCT/CN2010/002055, filed December 16, 2010, entitled **CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF**. ASSIGNOR and ASSIGNEE hereby confirm and declare that this Assignment, together with the Assignment-A, sets forth the entire agreement between the parties concerning the subject matters thereof. In the event of any inconsistencies between the provisions of this Assignment and the provisions of Assignment-A, the terms of this Assignment shall govern.

We hereby authorize the Commissioner of Patents of the United States, and other Patent Offices to issue to said ASSIGNEE in accordance with this Assignment any and all patents on the inventions disclosed in the applications referred herein.

We hereby agree that we will, at any time, upon the request, but at the expense of the ASSIGNEE or its legal representatives, (i) execute all divisional, continuation, continuation-in-part, substitute, renewal, reissue, reexamination, and all other patent applications or other documents on any and all of the foregoing inventions and discoveries for the United States and all other countries; (ii) execute all rightful oaths, assignments, powers of attorney and other papers; (iii) communicate to said ASSIGNEE and its legal representatives all facts known and documents available to the undersigned relating to the foregoing inventions and the history thereof; (iv) testify in all legal proceedings, and generally do everything possible which the ASSIGNEE and its legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for the foregoing inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said ASSIGNEE.

We hereby covenant with said ASSIGNEE that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

We hereby authorize ASSIGNEE or its representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision

shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

Assignor: 魏光文
Guangwen WEI

Date: October 22, 2015

Witness: 朱明
(signature)

Zuoming
(printed name of witness)

Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's Republic of China
(address of witness)

Assignor: 王大成
Dacheng WANG


Date: 2015.10.22 2015

Witness: 刘明芳
(signature)


Mingfang Liu
(printed name of witness)

Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's Republic of China
(address of witness)

Assignee: 魏光文
Guangwen WEI
Sichuan Huiyang Life Science & Technology Corp



Date: October 22, 2015

Witness: 
(signature)

Zuoming
(printed name of witness)

Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's
Republic of China
(address of witness)

SCHEDULE A

	Docket #	Title
1	1394-A-PCT-AU	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Australian Patent Application No. 2010333574, Filed June 28, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
2	1394-A-PCT-CA	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Canadian Patent Application No. 2,784,624, Filed June 15, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
3	1394-A-PCT-CN	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Chinese Patent No. 201080057897.1, previously Chinese Patent Application No. 201080057897.1, Filed June 18, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
4	1394-A-PCT-CN-HK	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Hong Kong Standard Patent Application No. 13104725.9, Filed April 18, 2013, based on Chinese Patent Application No. 201080057897.1, Filed June 18, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
5	1394-A-PCT-EP	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , European Patent Application No. 10836926.5, Filed July 18, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
6	1394-A-PCT-IN	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Indian Patent Application No. 6187/DELNP/2012, Filed July 12, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN

		200910259339.2, Filed December 18, 2009
7	1394-A-PCT-JP	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Japanese Patent Application No. 2012-543445, Filed June 15, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
8	1394-A-PCT-KR	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Korean Patent Application No. 10-2012-7017945, Filed July 10, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
9	1394-A-PCT-MY	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Malaysian Patent Application No. PI2012002756, Filed December 16, 2010, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
10	1394-A-PCT-SG	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Singapore Patent No. 181785, previously Singapore Patent Application No. 2012044889, Filed July 15, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
11	1394-A1-PCT-SG	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , Singapore Patent Application No. 10201408472T, Filed December 18, 2014, Divisional Application of Singapore Patent Application No. 2012044889, Filed July 15, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
12	1394-A-PCT-US	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF , U.S. Patent No. 8,846,025, previously U.S. Serial No. 13/516,947; Filed June 18, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
13	1394-A1-PCT-US	CRYSTALLINE RECOMBINANT INTERFERON WITH

		ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF, U.S. Serial No. 14/461,360; Filed August 15, 2014, which is a continuation application of U.S. Serial No. 13/516,947; Filed June 18, 2012, corresponding to International Application No. PCT/CN2010/002055, Filed December 16, 2010, claiming the benefit of CN 200910259339.2, Filed December 18, 2009
14	1394-B-US	CRYSTALLINE RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF, U.S. Patent No. 8,415,151, previously U.S. Serial No. 12/971,956, Filed December 17, 2010, which claims benefit of U.S. Serial No. 61/289,494, filed December 23, 2009 and which claims benefit of Chinese Application 200910259339.2, filed December 18, 2009